Literature DB >> 24592015

The effects of GnRH analogs on serum and follicular fluid leptin levels and pregnancy outcomes in short protocols of assisted reproductive technology.

Mete Ahmet Ergenoğlu1, Ahmet Özgür Yeniel1, Ayşin Akdoğan2, Ege Nazan Tavmergen Göker1, Erol Tavmergen1.   

Abstract

OBJECTIVE: To determine serum and follicular leptin levels in patients using gonadotropin releasing hormone agonist and antagonist in Assisted Reproductive Technology short protocol cycles and to evaluate pregnancy outcomes.
MATERIAL AND METHODS: Patients randomly selected to join assisted reproductive technology cycles during February 2004-July 2004 were enrolled in this study. Group 1 consisted of 21 patients receiving r FSH+ GnRH agonists, whereas Group 2 consisted of 34 patients who received r FSH +GnRH antagonists. During the ovulation induction period 5 serum samples were collected (induction day 1, day 3 or antagonist starting day, human chorionic hormone day, oocyte pickup day, and twelfth day of embryo transfer). Follicular fluid samples were collected to be evaluated for leptin, estradiol, prolactin and luteinizing hormone.
RESULTS: There was no difference in age, basal FSH, basal LH, and basal E2 between groups. Serum leptin levels were similar in both groups. Also, when each group's serum leptin levels were evaluated according to the presence of pregnancy, there was no significant difference in both groups. When follicle leptin levels were evaluated according to the existence of pregnancy, in both groups the follicle leptin levels were lower in pregnant participants but this difference was not statistically significant. When obesity is defined as body mass index over 26.5, there is a correlation between obesity and leptin levels in Group 2.
CONCLUSION: Our results have shown that both agonists and antagonists have similar efficacy and effect in poor responder women. Leptin levels in either groups, whether pregnant or non-pregnant were not statistically different. This result shows the need for more studies on leptin in infertility.

Entities:  

Keywords:  ART; GnRH agonist; GnRH antagonist; leptin; prolactin

Year:  2012        PMID: 24592015      PMCID: PMC3939144          DOI: 10.5152/jtgga.2012.10

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  39 in total

1.  Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.

Authors:  C Albano; R E Felberbaum; J Smitz; H Riethmüller-Winzen; J Engel; K Diedrich; P Devroey
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

2.  The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure.

Authors:  A Kennedy; T W Gettys; P Watson; P Wallace; E Ganaway; Q Pan; W T Garvey
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

3.  A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.

Authors:  M Wikland; C Bergh; K Borg; T Hillensjö; C M Howles; A Knutsson; L Nilsson; M Wood
Journal:  Hum Reprod       Date:  2001-08       Impact factor: 6.918

4.  Serum leptin levels during the menstrual cycle of healthy fertile women.

Authors:  N D Quinton; S M Laird; M A Okon; T C Li; R F Smith; R J Ross; A I Blakemore
Journal:  Br J Biomed Sci       Date:  1999       Impact factor: 3.829

Review 5.  Leptin in humans: lessons from translational research.

Authors:  Susann Blüher; Christos S Mantzoros
Journal:  Am J Clin Nutr       Date:  2009-01-28       Impact factor: 7.045

6.  Serum leptin concentrations in patients with severe ovarian hyperstimulation syndrome during in vitro fertilization-embryo transfer treatment.

Authors:  Hiroaki Shibahara; Yuki Hirano; Tatsuya Suzuki; Satoru Takamizawa; Mitsuaki Suzuki
Journal:  Fertil Steril       Date:  2004-09       Impact factor: 7.329

7.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

8.  Follicular development and early luteal function of conception and non-conceptional cycles after human in-vitro fertilization: endocrine correlates.

Authors:  C M Howles; M C Macnamee; R G Edwards
Journal:  Hum Reprod       Date:  1987-01       Impact factor: 6.918

9.  Recombinant ob protein reduces feeding and body weight in the ob/ob mouse.

Authors:  D S Weigle; T R Bukowski; D C Foster; S Holderman; J M Kramer; G Lasser; C E Lofton-Day; D E Prunkard; C Raymond; J L Kuijper
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

10.  Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.

Authors:  R Frydman; J Belaisch-Allart; I Parneix; R Forman; A Hazout; J Testart
Journal:  Fertil Steril       Date:  1988-09       Impact factor: 7.329

View more
  1 in total

1.  Maternal age and intracytoplasmic sperm injection outcome in infertile couples at Khartoum, Sudan.

Authors:  Mohamed Ahmed; Osama Shareef; Ishag Adam; Duria Rayis
Journal:  F1000Res       Date:  2015-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.